Loading stock data…
Boston Scientific Corporation develops (BSX)
$44.31+0.73 (+1.69%)
Market OpenUpdated 1:51 PM EDT
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Boston Scientific Corporation in the Healthcare sector is trading at $44.31 with a market capitalization of $69.1B. Wall Street consensus targets $72.43 (28 analysts), implying a +63.4% move over the next 12 months. The stock is currently near its 52-week low of $42.20, remaining 40.5% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +63.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.20B↓ | $5.29B↑ | $5.07B | $5.06B↑ | $4.66B |
| Gross Profit | $3.61B↓ | $3.68B↑ | $3.54B↑ | $3.42B↑ | $3.21B |
| Operating Income | $1.07B↑ | $1.04B↓ | $1.05B↑ | $943.00M↑ | $937.00M |
| Net Income | $1.34B↑ | $672.00M↓ | $755.00M↓ | $797.00M↑ | $674.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and tre...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$69.09B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
13.78%
Volume
Today's trading volume
11.05M
Recent News
Boston Scientific (BSX) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
6 Medical-Device Stocks to Buy After a Massive Selloff
Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.
Boston Scientific (BSX) Enrolls First Patients In Global Faraflex AFib Trial
Boston Scientific (NYSE:BSX) has enrolled the first patients in the global FARADIGM trial. The study evaluates the Faraflex pulsed field ablation device for the treatment of atrial fibrillation. This milestone marks the formal start of large scale clinical testing for the Faraflex system. Boston Scientific is a major player in cardiac rhythm and electrophysiology devices, and the FARADIGM trial adds another clinical program to that portfolio. Atrial fibrillation treatments have been an area...
Boston Scientific (BSX) Stock Still Looks Undervalued Following Its 58% Slump
Boston Scientific stock has had a tough run over the past year, yet the valuation checks still lean supportive, setting up a clear tension between recent share price weakness and what the broader metrics suggest about value. Boston Scientific shares are down about 58.1% over the past year, which sharply resets expectations around what investors are willing to pay for the business. Upcoming earnings and progress integrating recent device acquisitions may support sentiment, while ongoing Class...
Boston Scientific (BSX) Recalls Put Focus On Whether The Stock Still Looks Undervalued
Recall driven attention on Boston Scientific stock Boston Scientific (BSX) is back in focus after a series of voluntary recalls for its CRE and CRE Pro Wireguided gastrointestinal devices, tied to potential sterile pouch breaches across widely distributed product lots. With more than 81,000 units cited in individual recall notices and a worldwide distribution footprint, the situation brings product quality controls, potential regulatory implications and timing before the upcoming earnings...